Inhalation Forms of Ambroxol in the Therapy of Respiratory Tract Secretory-Evacuation Disorders in Acute Bronchitis in Children

Authors

  • L.S. Ovcharenko State Institution «Zaporizhya Medical Academy of Postgraduate Education of Ministry of Healthcare of Ukraine», Zaporizhya
  • A.A. Vertegel State Institution «Zaporizhya Medical Academy of Postgraduate Education of Ministry of Healthcare of Ukraine», Zaporizhya
  • T.G. Andriyenko State Institution «Zaporizhya Medical Academy of Postgraduate Education of Ministry of Healthcare of Ukraine», Zaporizhya
  • N.V. Zhikhareva State Institution «Zaporizhya Medical Academy of Postgraduate Education of Ministry of Healthcare of Ukraine», Zaporizhya
  • I.V. Samokhin State Institution «Zaporizhya Medical Academy of Postgraduate Education of Ministry of Healthcare of Ukraine», Zaporizhya
  • V.Yu. Tkachenko State Institution «Zaporizhya Medical Academy of Postgraduate Education of Ministry of Healthcare of Ukraine», Zaporizhya

DOI:

https://doi.org/10.22141/2224-0551.3.54.2014.75994

Keywords:

children, bronchitis, ambroxol, inhalation, nebulizer

Abstract

The mucoactive therapy of children aged 1 to 5 years with acute bronchitis using drug Lasolvan solution for oral and inhalation use or syrup for oral use Lasolvan is highly effective and safe method for management of respiratory tract secretory-evacuation disorders. Given the chance of inhalation therapy, effective treatment of choice, while maintaining a high safety profile, is inhalation of Lasolvan solution for oral and inhalation use by nebulizer. More rapid decline in the clinical severity of acute bronchitis in children treated with inhaled Lasolvan associated with accelerated recovery of disturbed secretory-evacuation mechanisms of bronchial tree.

References

Наказ МОЗ України № 18 від 13.01.05 «Про затвердження Протоколів надання медичної допомоги дітям за спеціальністю «дитяча пульмонологія».

Malerba M. Ambroxol in the 21st century: pharmacological and clinical update / M. Malerba, B. Ragnoli // Expert Opin. Drug Metab. Toxicol. — 2008. — Vol. 4 (8). — P. 1119-1129.

Wirtz H.R. Effekt von Ambroxol auf die Surfactantsekretion und-synthese von isolierten alveolaren Typ-II-Zellen // Pneumologie. — 2000. — Vol. 54. — P.278-283.

Antioxidant properties of Ambroxol / Nowak D., Antczak A., Krol M. [et al.] // Free Radic. Biol. Med. — 1994. — Vol. 16. — Р. 517-522.

Yang B. Ambroxol suppresses influenza-virus proliferation in the mouse airway by increasing antiviral factor levels / B. Yang, D.F. Yao, M. Ohuchi // Eur. Resp. J. — 2002. — Vol. 19. — P. 952-958.

Influence of ambroxol on lung tissue penetration of amoxicillin / Spatola J. [et al.] // Drug Res. — 1987. — Vol. 37. — P. 965-966.

Ambroxol inhibits interleukin-1 and tumor necrosis factor production in human mononuclear cells / M. Bianchi, A. Mantovani, A. Errol [et al.] // Agents Actions. — 1990. — Vol. 31. — P. 275-279.

Ambroxol inhibits the release of histamine, leukotrienes and cytokines from human leukocytes and mast cells / B.F. Gibbs, W. Schmutzler, I.B. Vollrath [et al.] // Inflamm. Res. — 1999. — Vol. 48. — P. 86-93.

Lis G. Bronchiolitis. We know what is the reason and how to treat // Przegl. Lek. — 2011. — Vol. 68 (1). — P. 25-28.

Wang J. Bronchitis obliterans in children: report of two cases and literature review / J. Wang, Y. Yang, S.Y. Zhao // Zhonghua Er. Ke. Za. Zhi. — 2010. — Vol. 48 (10). — P. 764-766.

Савченко В.Н. Формализованная система базовых клинических показателей для оценки состояния больных с хроническими необструктивными и обструктивными болезнями легких // Украинский пульмонологический журнал. — 2001. — № 2. — С. 46-50.

Published

2014-06-19

Issue

Section

Clinical Pediatrics